Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/1078155217732141
Abstract: 5-fluorouracil and capecitabine are chemotherapeutic agents commonly used to treat solid malignancies. Increased susceptibility to 5-fluorouracil or capecitabine, caused by impaired clearance, dihydropyrimidine dehydrogenase deficiency, or other genetic mutations in the enzymes that metabolize 5-fluorouracil… read more here.
Keywords: dihydropyrimidine dehydrogenase; dihydropyrimidine; uridine triacetate; patient homozygous ... See more keywords